Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


1 Clin Infect Dis
1 Infect Immun
1 J Infect
3 J Infect Dis
3 Lancet
1 N Engl J Med
1 Pediatrics
5 PLoS One
1 Proc Natl Acad Sci U S A
17 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Clin Infect Dis

  1. MCCONEGHY KW, Hur K, Dahabreh IJ, Jiang R, et al
    Early Mortality After the First Dose of Coronavirus Disease 2019 Vaccination: A Target Trial Emulation.
    Clin Infect Dis. 2024 Feb 6:ciad604. doi: 10.1093.
    PubMed         Abstract available

    Infect Immun

  2. DEJONG MA, Wolf MA, Bitzer GJ, Hall JM, et al
    BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.
    Infect Immun. 2024 Feb 7:e0022323. doi: 10.1128/iai.00223.
    PubMed         Abstract available

    J Infect

  3. AL-ABRI SS, Abuhasan MY, Albayat SSA, Bai X, et al
    Meningococcal disease in the Middle East: A report from the Global Meningococcal Initiative.
    J Infect. 2024;88:71-76.
    PubMed         Abstract available

    J Infect Dis

  4. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Shriver M, et al
    Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge.
    J Infect Dis. 2024 Feb 8:jiae062. doi: 10.1093.
    PubMed         Abstract available

  5. BURKE RM, Payne DC, McNeal M, Conrey SC, et al
    Correlates of Rotavirus Vaccine Shedding and Seroconversion in a U.S. Cohort of Healthy Infants.
    J Infect Dis. 2024 Feb 8:jiae055. doi: 10.1093.
    PubMed         Abstract available

  6. HU X, Karthigeyan KP, Herbek S, Valencia SM, et al
    Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
    J Infect Dis. 2024 Feb 7:jiad593. doi: 10.1093.
    PubMed         Abstract available


    Africa's First Routine Malaria Vaccination Campaign Begins.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0170.

  8. NORMAN M, Magnus MC, Soderling J, Juliusson PB, et al
    Neonatal Outcomes After COVID-19 Vaccination in Pregnancy.
    JAMA. 2024;331:396-407.
    PubMed         Abstract available

  9. FELDSTEIN LR, Britton A, Grant L, Wiegand R, et al
    Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    JAMA. 2024;331:408-416.
    PubMed         Abstract available


    Routine malaria vaccinations begin.
    Lancet. 2024;403:423.

  11. DATOO MS, Dicko A, Tinto H, Ouedraogo JB, et al
    Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
    Lancet. 2024 Feb 1:S0140-6736(23)02511-4. doi: 10.1016/S0140-6736(23)02511.
    PubMed         Abstract available

  12. MOORTHY V, Hamel MJ, Smith PG
    Malaria vaccines for children: and now there are two.
    Lancet. 2024 Feb 1:S0140-6736(23)02743-5. doi: 10.1016/S0140-6736(23)02743.

    N Engl J Med

  13. HIGGINS DM, O'Leary ST
    The Risks of Normalizing Parental Vaccine Hesitancy.
    N Engl J Med. 2024;390:485-487.


  14. CARDEMIL CV, Cao Y, Posavad CM, Badell ML, et al
    Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.
    Pediatrics. 2024 Feb 9:e2023064252. doi: 10.1542/peds.2023-064252.
    PubMed         Abstract available

    PLoS One

  15. UDOAKANG AJ, Nganyewo NN, Djomkam Zune AL, Olwal CO, et al
    Knowledge, attitude and perception towards COVID-19 among representative educated sub-Saharan Africans: A cross-sectional study during the exponential phase of the pandemic.
    PLoS One. 2024;19:e0281342.
    PubMed         Abstract available

  16. SARMIENTO-MEDINA MI, de Amaya MP, Villamizar-Gomez L, Gonzalez-Coba AC, et al
    High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study.
    PLoS One. 2024;19:e0297579.
    PubMed         Abstract available

  17. LAUE T, Junge N, Leiskau C, Mutschler F, et al
    Diminished measles immunity after paediatric liver transplantation-A retrospective, single-centre, cross-sectional analysis.
    PLoS One. 2024;19:e0296653.
    PubMed         Abstract available

  18. AGIMAS MC, Asmamaw M, Mekonen N, Mamo F, et al
    Spatial pattern and associated factors of timely vaccination in Ethiopia using EDHS-2016 data: A multilevel and spatial analysis.
    PLoS One. 2024;19:e0296123.
    PubMed         Abstract available

  19. ASADI-POOYA AA, Nemati M, Shahisavandi M, Nemati H, et al
    How does COVID-19 vaccination affect long-COVID symptoms?
    PLoS One. 2024;19:e0296680.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  20. XU D, Powell AE, Utz A, Sanyal M, et al
    Design of universal Ebola virus vaccine candidates via immunofocusing.
    Proc Natl Acad Sci U S A. 2024;121:e2316960121.
    PubMed         Abstract available


  21. WELDEGEBRIEL GG, Okot C, Majingo N, Oumer NJ, et al
    Resurgent rotavirus diarrhoea outbreak five years after introduction of rotavirus vaccine in Botswana, 2018.
    Vaccine. 2024 Feb 7:S0264-410X(24)00108-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  22. CHEN M, Feng X, Liu J, Wang J, et al
    Prokaryote-derived phosphorylated Tau epitope vaccine is immunogenic and non-T-cell activated in the mice model.
    Vaccine. 2024 Feb 7:S0264-410X(23)01517-7. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  23. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  24. LAMBACH P, Orenstein W, Silal S, Sbarra AN, et al
    Report from the World Health Organization's immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13 September 2023.
    Vaccine. 2024 Feb 6:S0264-410X(24)00160-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  25. SOBLE A, Ko M, Gilchrist S, Malvolti S, et al
    A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches.
    Vaccine. 2024 Feb 6:S0264-410X(23)01493-7. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  26. KOHLI K, Jain B, Dee EC, Ho BL, et al
    Addressing cultural and political drivers of vaccine hesitancy: Considerations for the African and Asian contexts.
    Vaccine. 2024 Feb 6:S0264-410X(24)00159-2. doi: 10.1016/j.vaccine.2024.

  27. KHAN A, Hussain I, Rhoda DA, Umer M, et al
    Determinants of immunization in polio super high-risk union councils of Pakistan.
    Vaccine. 2024;42:583-590.
    PubMed         Abstract available

  28. FERRERAS-COLINO E, Contreras M, Risalde MA, Sevilla IA, et al
    Heat-inactivated mycobacteria activate the toll-like receptor 2 and 4 pathways in the zebrafish model of tuberculosis.
    Vaccine. 2024;42:403-409.
    PubMed         Abstract available

  29. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    PubMed         Abstract available

  30. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  31. WANG ZJ, Zhang RR, Wu M, Zhao H, et al
    Development of a live-attenuated chimeric vaccine against the emerging Usutu virus.
    Vaccine. 2024 Feb 2:S0264-410X(24)00098-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  32. LI D, Han M, Cao Y, Du J, et al
    Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine.
    Vaccine. 2024 Feb 2:S0264-410X(24)00062-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  33. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
    Vaccine. 2024 Feb 2:S0264-410X(24)00068-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  34. HWANG YH, Byeon Y, Ahn SH, Kim MY, et al
    Live attenuated smallpox vaccine candidate (KVAC103) efficiently induces protective immune responses in mice.
    Vaccine. 2024 Feb 2:S0264-410X(24)00076-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  35. HOUY N, Flaig J
    Value of information dynamics in Disease X vaccine clinical trials.
    Vaccine. 2024 Feb 3:S0264-410X(24)00075-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  36. KIM NE, Kim MJ, Park BJ, Kwon JW, et al
    A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses.
    Vaccine. 2024 Feb 5:S0264-410X(24)00114-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  37. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.